- Home
- NTRB vs DTIL Comparison
NTRB vs DTIL Comparison
Compare NTRB & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- DTIL
- Stock Information
- Founded
- NTRB 2016
- DTIL 2006
- Country
- NTRB United States
- DTIL United States
- Employees
- NTRB N/A
- DTIL N/A
- Industry
- NTRB Industrial Specialties
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- NTRB Health Care
- DTIL Health Care
- Exchange
- NTRB Nasdaq
- DTIL Nasdaq
- Market Cap
- NTRB 59.1M
- DTIL 51.6M
- IPO Year
- NTRB N/A
- DTIL 2019
- Fundamental
- Price
- NTRB $7.50
- DTIL $4.79
- Analyst Decision
- NTRB Buy
- DTIL Strong Buy
- Analyst Count
- NTRB 1
- DTIL 2
- Target Price
- NTRB $13.00
- DTIL $47.00
- AVG Volume (30 Days)
- NTRB 82.0K
- DTIL 85.2K
- Earning Date
- NTRB 05-30-2025
- DTIL 07-31-2025
- Dividend Yield
- NTRB N/A
- DTIL N/A
- EPS Growth
- NTRB N/A
- DTIL N/A
- EPS
- NTRB N/A
- DTIL N/A
- Revenue
- NTRB $2,398,437.00
- DTIL $51,141,000.00
- Revenue This Year
- NTRB $560.75
- DTIL N/A
- Revenue Next Year
- NTRB $588.39
- DTIL $30.20
- P/E Ratio
- NTRB N/A
- DTIL N/A
- Revenue Growth
- NTRB 18.92
- DTIL N/A
- 52 Week Low
- NTRB $3.72
- DTIL $3.61
- 52 Week High
- NTRB $11.78
- DTIL $11.09
- Technical
- Relative Strength Index (RSI)
- NTRB 59.79
- DTIL 44.86
- Support Level
- NTRB $7.00
- DTIL $4.20
- Resistance Level
- NTRB $7.90
- DTIL $5.29
- Average True Range (ATR)
- NTRB 0.66
- DTIL 0.36
- MACD
- NTRB -0.01
- DTIL -0.03
- Stochastic Oscillator
- NTRB 37.45
- DTIL 36.88
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.